secwatch.observer — SEC 8-K summary
======================================

Issuer:     Aprea Therapeutics, Inc. (APRE)
CIK:        0001781983
Form:       8-K
Filed at:   2022-11-16T23:59:59+00:00
Accession:  0001104659-22-119551
Event type: regulatory
Sentiment:  positive
Materiality: 0.55
Item codes: 3.01
LLM model:  deepseek-v4-flash:cloud@v2

Aprea Therapeutics regains compliance with Nasdaq minimum $10M stockholders' equity requirement
--------------------------------------------------------------------------------

- Received deficiency letter on Aug 15, 2022 for failing minimum $10M stockholders' equity rule.
- Based on Q3 2022 10-Q showing equity of ~$26.6M, Nasdaq confirmed compliance regained.
- Listing on Nasdaq Global Select Market continues without risk of delisting.

Source:
  EDGAR index:    https://www.sec.gov/Archives/edgar/data/1781983/000110465922119551/0001104659-22-119551-index.htm
  Primary doc:    https://www.sec.gov/Archives/edgar/data/1781983/000110465922119551/tm2230665d1_8k.htm
  HTML page:      https://secwatch.observer/filing/0001104659-22-119551

License: Source filings: public domain (SEC EDGAR). Summaries (headline + bullets): CC-BY-4.0; attribute https://secwatch.observer